ESMO 2024 | TREAT ctDNA: early elacestrant intervention for ER+/HER2- breast cancer

Michail Ignatiadis • 14 Sep 2024

ESMO 2024

Breast Cancer Elacestrant

Michail Ignatiadis, MD, PhD, Jules Bordet Institute, Brussels, Belgium, comments on the TREAT ctDNA trial (NCT05512364) of elacestrant versus standard endocrine therapy in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer experiencing circulating tumor DNA (ctDNA) relapse. By using ctDNA as a biomarker, the trial aims to detect molecular recurrence early, potentially delaying distant metastasis onset. The study monitors outcomes such as distant metastasis-free survival, quality of life, and overall survival, with follow-up using imaging modalities over three years across multiple countries. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.